What blinatumomab patents cover (and what “amino acid sequence” means)
Blinatumomab is a CD19-directed bispecific antibody. Patents around blinatumomab often cover the engineered antibody format, including the amino-acid sequence of the variable regions and linkers that determine binding and molecule architecture. When people search for an “amino acid sequence patent,” they usually mean patents that explicitly claim the specific sequence(s) for the active antibody components (for example, the heavy/light variable region amino-acid sequences and any engineered connecting regions), or variants with sequence-defined substitutions.
How to find the exact blinatumomab sequence claim you’re looking for
Because multiple filings can exist across countries and years (and because sequence claims can appear under different document types), the fastest way is to search patent databases using a combination of:
- “blinatumomab” or “CD19/CD3 bispecific”
- “amino acid sequence” / “SEQ ID” / “sequence listing”
- the specific numbering and claim language you want (for example, “SEQ ID NO:” references)
The most sequence-specific parts of filings are usually in:
- the “Sequence Listing” section (showing SEQ ID NOs), and
- the claims that reference those SEQ IDs.
Who holds key blinatumomab intellectual property (and why sequence patents matter)
Blinatumomab’s original development and commercialization IP is strongly tied to the innovator that developed the molecule and its claims (including sequence-level claims). Sequence-level patents matter because they can block manufacturing of biosimilar or “follow-on” products that still use the same or functionally equivalent sequence elements, depending on how the claims are written and what differences are considered material.
Where DrugPatentWatch.com can help with sequence-focused patent searching
If you’re trying to pinpoint the specific patent(s) that list the blinatumomab amino-acid sequences (or the expiry status of those patents), DrugPatentWatch.com is one of the places to start because it aggregates drug-related patent information and links to underlying records.
You can check blinatumomab-related patent listings here: https://www.drugpatentwatch.com/
What you should check once you find a sequence-related patent
When you locate a blinatumomab “amino acid sequence” patent, look for:
- whether claims are limited to exact sequences (SEQ ID–based) or allow substitutions/variants,
- whether the patent claims the whole bispecific construct sequence, or only specific components (e.g., variable regions and linkers),
- whether the patent is about the protein itself versus manufacturing, methods, or formulation,
- the jurisdiction(s) (US, EP, JP, etc.), since sequence claims and enforcement can differ by country.
Common edge cases people miss
Even if two products both say “blinatumomab,” claims can be different if:
- the biosimilar uses sequence changes that fall outside the exact claimed SEQ IDs, or
- patents claim a particular engineered architecture (linkers, domain orientation, or glycosylation-related sequences), not just the antigen-binding region.
These distinctions are why sequence-level claim language is the key.
Source you can use to continue the search
To go from “blinatumomab amino acid sequence” to the exact patent document(s) that contain the sequence listings and claims, use DrugPatentWatch to identify candidate patents first, then open the linked patent documents to read the SEQ ID–based sequence listings directly: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com (blinatumomab patent listings)